European Association for the Study of the Liver Congress 2026 (EASL 2026)
Barcelona, Spain 27 May 2026 - 30 May 2026
Seladelpar improves liver outcomes in cirrhosis patients with PBC, portal hypertension
Treatment with seladelpar for 4 years yields consistent biochemical efficacy, with no new safety concerns, among patients with cirrhosis and primary biliary cholangitis (PBC), as shown by interim results from the open-label ASSURE study.
Seladelpar improves liver outcomes in cirrhosis patients with PBC, portal hypertension
21 Jun 2026
FMT reduces alcohol cravings, relapse rates in patients with ALD
Faecal microbiota transplantation (FMT) significantly improves alcohol abstinence and reduces relapse episodes for up to 6 months in patients with alcohol-related liver disease (ALD) and alcohol use disorder (AUD), as shown in a recent study presented at EASL 2026.
FMT reduces alcohol cravings, relapse rates in patients with ALD
16 Jun 2026
EPICS-III shows saroglitazar potential for select PBC patients
In the phase IIb/III EPICS-III study, the dual PPAR-α/γ agonist saroglitazar improves biochemical response (BCR) rates among individuals with primary biliary cholangitis (PBC) who had an inadequate response or intolerance to ursodeoxycholic acid (UDCA).